Paper · 42657238
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 54
Download this page as JSON| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,124,322 | Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies. | Regen Ther | 2021 | https://conductscience.org/library/papers/34124322 | PubMed |
| 2 | 34,956,607 | Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. | Interface Focus | 2022 | https://conductscience.org/library/papers/34956607 | PubMed |
| 3 | 40,110,334 | The dynamic role of soluble urokinase plasminogen activator receptor (suPAR) in monitoring coagulation dysfunction during COVID-19 progression: a review. | Ann Med Surg (Lond) | 2025 | https://conductscience.org/library/papers/40110334 | PubMed |
| 4 | 40,092,217 | Efficient Control of IL-6, CRP and Ferritin in COVID-19 Patients With Two Variants of Beta-1,3-1,6 Glucans in Combination: An Open-Label, Prospective, Randomised Clinical Trial. | Glob Adv Integr Med Health | 2025 | https://conductscience.org/library/papers/40092217 | PubMed |
| 5 | 37,427,016 | Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention. | Pathog Immun | 2023 | https://conductscience.org/library/papers/37427016 | PubMed |
| 6 | 32,412,405 | Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation. | Eur J Rheumatol | 2020 | https://conductscience.org/library/papers/32412405 | PubMed |
| 7 | 40,729,168 | COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine. | Reports (MDPI) | 2023 | https://conductscience.org/library/papers/40729168 | PubMed |
| 8 | 35,621,229 | The role of cytokines and their antagonists in the treatment of COVID-19 patients. | Rev Med Virol | 2023 | https://conductscience.org/library/papers/35621229 | PubMed |
| 9 | 39,359,765 | Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/39359765 | PubMed |
| 10 | 36,851,766 | Hyperinflammatory Response in COVID-19: A Systematic Review. | Viruses | 2023 | https://conductscience.org/library/papers/36851766 | PubMed |
| 11 | 33,559,152 | Biomarker-Guided Individualization of Antibiotic Therapy. | Clin Pharmacol Ther | 2021 | https://conductscience.org/library/papers/33559152 | PubMed |
| 12 | 38,543,226 | Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38543226 | PubMed |
| 13 | 35,208,467 | Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. | Medicina (Kaunas) | 2022 | https://conductscience.org/library/papers/35208467 | PubMed |
| 14 | 35,269,564 | COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35269564 | PubMed |
| 15 | 34,013,158 | Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage. | Euro Med J Innov | 2021 | https://conductscience.org/library/papers/34013158 | PubMed |
| 16 | 37,419,534 | Postacute Sequelae of SARS-CoV-2: Musculoskeletal Conditions and Pain. | Phys Med Rehabil Clin N Am | 2023 | https://conductscience.org/library/papers/37419534 | PubMed |
| 17 | 34,248,921 | Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. | Front Microbiol | 2021 | https://conductscience.org/library/papers/34248921 | PubMed |
| 18 | 39,861,166 | Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/39861166 | PubMed |
| 19 | 41,112,249 | Multi-omics and machine learning identify novel biomarkers and therapeutic targets of COVID-19. | Front Immunol | 2025 | https://conductscience.org/library/papers/41112249 | PubMed |
| 20 | 38,359,836 | Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. | Med | 2024 | https://conductscience.org/library/papers/38359836 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/42657238/references